Malignant: A Physician's Case That Policy, Not Just Biology, Fails Cancer Patients

Malignant: How Bad Policy and Bad Evidence Harm People with Cancer was published by Johns Hopkins University Press in 2020. Its author, Vinayak K. Prasad, is a practicing oncologist and health-policy researcher whose academic work has focused on evidence quality in medicine, including a body of research on what he and colleagues call medical reversal, the phenomenon of a widely adopted practice later shown, through better evidence, not to work.

The book is not a memoir and has no single patient's story at its center. It is a sustained policy argument, aimed at how cancer drugs get approved, how screening tests get recommended, and how financial incentives inside the healthcare and pharmaceutical systems can shape those decisions in ways that do not always serve patients.

Prasad's central claim is that oncology, more than many fields, has adopted shortcuts in how new treatments are evaluated, particularly the use of surrogate endpoints such as tumor shrinkage, in place of the outcomes that matter directly to patients: living longer, or living better. He argues that these shortcuts, combined with the financial incentives on drug companies, hospitals and journals, have allowed treatments and tests to reach patients before the evidence supporting them is as strong as patients likely assume it is.

The book is explicitly a critique from inside the field. Prasad treats patients as an oncologist, and frames his argument as an attempt to make oncology more accountable to its own evidentiary standards, not as an attack on cancer treatment itself.

The book is organized around a series of case studies and arguments, each built around a specific policy mechanism the author argues has gone wrong. Chapters examine FDA's accelerated approval pathway, which allows a drug to reach the market based on a surrogate endpoint before a confirmatory trial establishes an effect on survival, and cases where confirmatory trials were delayed, weak, or never conclusively completed.

Other sections address screening, including PSA testing for prostate cancer, treating it as a parallel case where enthusiasm for early detection outran the evidence that earlier detection reliably translates into lives saved, a critique that overlaps with the argument made a decade earlier in Overdiagnosed.

The book also examines the financial and institutional incentives Prasad argues distort these decisions: drug companies' incentive to seek approval on the fastest available pathway, the difficulty of running confirmatory trials once a drug is already on the market and available outside a trial, and the incentives within academic publishing and continuing medical education that Prasad argues can reward enthusiasm over rigor.

Prasad closes with recommendations for reform: stricter requirements for confirmatory trials to be completed and to show real clinical benefit, and calls for evidence standards that treat overall survival and quality of life, not surrogate markers alone, as the outcomes that matter for approval and for reimbursement decisions.

The book's strongest material is its use of FDA's own accelerated approval framework, which is real, named, and creates exactly the surrogate-endpoint dynamic Prasad describes. This is not a claim invented for the book; it is how the pathway is designed to work, with confirmatory trials as a built-in follow-up requirement.

Prasad's standing as a practicing oncologist and published health-policy researcher lends the argument real weight; his critique engages with the mechanics of drug approval and trial design in specific, checkable detail rather than in vague terms.

The book is also useful for naming, plainly, an uncomfortable structural reality: that the incentives facing a drug company seeking approval, a hospital seeking to offer the newest treatment, and a patient hoping for any additional option are not always aligned with the incentive to run a slow, rigorous confirmatory trial.

Prasad's positions on several specific drugs and screening tests discussed in the book are contested within oncology, and the book generally presents his side of active professional debates without extensive space for opposing expert views. A reader should treat the book as a strong argument from one respected but not uncontested position within the field, not as a settled consensus.

The book was published in 2020, and both FDA's own accelerated approval requirements and the specific drugs it discusses have moved since then. FDA has publicly acknowledged some of the same confirmatory-trial timeliness concerns Prasad raises and has taken steps in recent years to tighten enforcement, including withdrawing some accelerated approvals where confirmatory trials failed to confirm benefit. A reader should not assume the specific approval-pathway problems described for any one drug in the book still describe that drug's current status.

The book's tone is direct and, at points, sharply critical of specific researchers, companies and institutions. That directness is part of its argument, but it means the book reads more like advocacy for reform than a neutral survey, and a reader should weigh its claims against the current federal standards described below.

Prasad's own standard for evaluating a treatment claim, stated throughout the book, is a workable general tool: has the treatment been shown to improve overall survival or quality of life in a randomized trial, or only a surrogate marker such as tumor response or progression-free survival. A claim resting only on the surrogate marker is weaker than one with survival data behind it, even if both are described in the same confident language.

A second standard from the book is asking who benefits financially from a given claim being believed, and whether the study behind it was designed and funded independently of that interest. This does not make an industry-funded study wrong, but it is a reasonable prompt to look for independent confirmation.

Readers can apply the same tests to the book's own claims: check whether a specific drug or approval Prasad criticizes has since had its confirmatory trial completed, and what that trial showed, since that is exactly the kind of update that can move a claim from contested to resolved in either direction.

The book's screening critique focuses heavily on prostate cancer, and current USPSTF guidance reflects a broadly similar concern about overdiagnosis and overtreatment, arrived at through the Task Force's own evidence review rather than through the book's argument.

USPSTF currently grades PSA-based prostate cancer screening for men aged 55 to 69 as Grade C, meaning it should be an individual decision rather than a routine recommendation, citing a modest estimated benefit, about 1.3 prostate cancer deaths prevented per 1,000 men screened over 13 years, against considerable potential harms including false positives, overdiagnosis, and treatment complications such as incontinence and erectile dysfunction. For men 70 and older, USPSTF recommends against PSA-based screening, a Grade D.

On the drug-approval side, FDA's accelerated approval program page describes the pathway plainly: approval can be granted based on a surrogate endpoint "reasonably likely to predict clinical benefit," with the sponsor required to conduct confirmatory trials afterward to verify that benefit, and FDA retaining authority to withdraw approval if a confirmatory trial fails to confirm it. That FDA has, in recent years, publicly withdrawn some accelerated approvals under this authority is a partial answer to the book's central concern, showing the enforcement mechanism it argues for does operate, even if imperfectly and not always quickly.

For the fuller current picture on prostate screening specifically, see prostate cancer screening, for the broader overdiagnosis concept the book shares with Overdiagnosed, see cancer overdiagnosis.

It is worth being direct about where this book's argument sits relative to mainstream oncology practice today: it represents a serious, credentialed critique from within the field, not a fringe position, but it is also not the only view within oncology on how aggressively accelerated approval and screening enthusiasm should be curtailed. Many oncologists and health-policy researchers share specific concerns Prasad raises, particularly around confirmatory trial timeliness, while disagreeing with him on how broadly those concerns should be applied to specific drugs or screening programs he singles out. Readers encountering strong claims in either direction, that a specific accelerated-approval drug is essentially unproven, or conversely that any criticism of accelerated approval amounts to denying patients access to promising treatment, should treat both as claims to check against the specific trial data available for that specific drug, rather than resolving the question from general principle alone. The book is most useful as a framework for asking the right questions of a specific case, not as a verdict on any specific treatment a reader might currently be considering.

This book suits a reader who wants a pointed, well-informed critique of how cancer drugs get approved and how screening gets recommended, from someone inside the field willing to name specific cases. It rewards a reader already comfortable with some statistical and policy vocabulary, or willing to look terms up as they go.

It does not suit a reader looking for a balanced survey of the accelerated approval debate; it presents one strong side of an active disagreement. It also does not suit a reader who wants the book to resolve, on its own, whether a specific treatment they have been offered is well-supported; that question needs a conversation with their own oncology team, informed by current evidence, not the book's 2020 case studies alone.

Cancer Explained is free and ad-free, and you can support this work if it helped.

• Wikipedia — Vinay Prasad
• FDA — Accelerated Approval Program
• USPSTF — Prostate Cancer: Screening

This page discusses Malignant for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care.